SCHEMBL7541191

SCHEMBL7541191

CCN(C(C)C)C(C)C.CCOC(=O)CNS(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.54
L3MBTL1 Q9Y468 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.48
LMNA P02545 2/20 0.48
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
MEP1B Q16820 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
PKM P14618 1/20 0.46
GAA P10253 2/20 0.46
HPGD P15428 2/20 0.45
KDM4E B2RXH2 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
HSD17B10 Q99714 1/20 0.43
ATM Q13315 1/20 0.43
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6506619 0.90 ALDH1A1 (0.64) ALDH1A1L3MBTL1SMN1; SMN2LMNACA1
SCHEMBL7522811 0.85 LMNA (0.52) ALDH1A1SMN1; SMN2LMNACA1CA2
SCHEMBL257480 0.79 ALDH1A1 (0.67) ALDH1A1L3MBTL1SMN1; SMN2LMNAKMT2A
SCHEMBL7261912 0.76 ALDH1A1 (0.64) ALDH1A1L3MBTL1SMN1; SMN2KMT2APKM
SCHEMBL7522814 0.76 LMNA (0.51) ALDH1A1L3MBTL1SMN1; SMN2LMNACA1
SCHEMBL28849841 0.75 ALDH1A1 (0.62) ALDH1A1L3MBTL1SMN1; SMN2LMNAMEP1B
SCHEMBL13917758 0.75 ALDH1A1 (0.62) ALDH1A1L3MBTL1SMN1; SMN2LMNAMEP1B
SCHEMBL7345656 0.75 ALDH1A1 (0.62) ALDH1A1L3MBTL1SMN1; SMN2LMNACA1
SCHEMBL20743746 0.74 MMP9 (0.49) ALDH1A1L3MBTL1SMN1; SMN2LMNACA1
SCHEMBL8285177 0.73 MEP1B (0.62) ALDH1A1SMN1; SMN2LMNAMEP1BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020028797-A1 N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists AMERICAN HOME PRODUCTS CORPORATION 2002-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028797-A1 N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists ADRB3, ADRB1, ADRB2 ALDH1A1 1800/4885L3MBTL1 3246/4885SMN1; SMN2 2852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.